Current therapy of myeloma induced renal failure

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 833-834

  Gertz, Morie ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CREATININE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; TAMM HORSFALL GLYCOPROTEIN; THALIDOMIDE;

ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MULTIPLE MYELOMA; NOTE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT RESPONSE;

BORONIC ACIDS; HUMANS; KIDNEY FAILURE; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 46749150457     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801972482     Document Type: Note

References (10)

1. Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q. and Dispenzieri, A. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, pp. 21-33.
2. Clark, W. F., Stewart, A. K., Rock, G. A., Sternbach, M., Sutton, D. M. and Barrett, B. J. (2005) Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med, 143, pp. 777-784.
3. Hutchison, C. A., Cockwell, P., Reid, S., Chandler, K., Mead, G. P. and Harrison, J. (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol, 18, pp. 886-895.
4. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Hayman, S. R., Kumar, S. and Leung, N. (2007) Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant, 39, pp. 605-611.
5. Tosi, P., Zamagni, E., Cellini, C., Cangini, D., Tacchetti, P. and Tura, S. (2004) Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol, 73, pp. 98-103.
6. Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J. B. and Knight, R. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol, 47, pp. 1466-1475.
7. Oakervee, H., Popat, R. and Cavenagh, J. D. (2007) Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leuk Lymphoma, 48, pp. 1910-1921.
8. Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R. and Srkalovic, G. (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 103, pp. 1195-1200.
9. Malani, A. K., Gupta, V. and Rangineni, R. (2006) Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol, 116, pp. 255-258.
10. Roussou, M., Kastritis, E., Migkou, M., Psimenou, E., Grapsa, I. and Matsouka, C. (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma, 49, pp. 882-887.